Apellis Pharmaceuticals (APLS) and Sobi said Thursday that the European Medicines Agency has validated an indication extension application for Aspaveli to treat C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.
The submission was based on the results from a phase 3 trial that met its primary endpoint by reducing proteinuria in pegcetacoplan-treated patients by 68% as compared to placebo, the companies added.
C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are two kinds of chronic kidney diseases without approved treatments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.